Psst… We received a tip…

It is 2029, and the Neuralink launch livestream looks perfect. The demo patient moving a cursor with their mind, and the crowd eating it up like the dystopic future finally showed up. Then the mood shifts. 

A few early clinics pause treatment after seeing unstable stimulation patterns during follow-up checks. A safety issue that makes doctors nervous and regulators start asking harder questions. 

That is the thing about brain-computer interfaces (BCI). The magic is in the demo, but the risk lives in the wiring. One bad pulse, one build-up of charge, one moment where an electrode pushes too far, and suddenly the real race is about protecting the person on the other end of the signal. 

This week’s patent comes from Huawei, and it goes after the safety layer underneath: the system that checks electrode voltage, catches dangerous charge build-up, and helps stop stimulation from turning risky. If the brain-computer boom is real, Huawei may already have patented one of the guardrails big players like Neuralink will need.

Huawei Technologies Co. filed this patent family first in China in March 2023, before later extending it internationally

This patent goes after the scary problem hiding underneath brain-computer interfaces of what happens when the electrode keeps a leftover charge, pushes too much voltage, or slips into a fault state that can hurt tissue or fry the hardware.

Every time the brain-computer interface electrode fires a stimulation pulse, it leaves behind a small residual charge. Huawei's system checks the electrode voltage during the gaps between pulses. If the voltage is still sitting too high when it should have settled, the system knows charge is lingering where it shouldn't be.

The fix is a cleanup pulse in the opposite direction. Too much positive charge left over? Push negative. Too much negative? Push positive. Then, once the big mess is handled, the system connects the electrode to a stable reference point and lets the last traces drain away. Hit the bulk of it, then mop up the rest.

That is one guardrail. The patent builds two more on top of it.

The second watches for fault conditions mid-pulse. If the voltage spikes past a threshold while the electrode is actively firing, the system treats it as a short-circuit risk, cuts the power connection, and reroutes through a current-limiting path so the correction doesn't create a new surge of its own.

The third monitors the chemistry at the boundary between electrode and tissue. Brain tissue is delicate. Push the wrong electrical conditions long enough and the chemistry at that interface can turn hostile. Huawei's system watches for that threshold and can throw an alert before damage accumulates.

The patent says this can sit inside a broader brain-computer interface system used for closed-loop control, disease treatment, or sensory reconstruction. That includes things like helping a system stimulate the right brain region after reading signals, or converting outside sensory information into stimulation that could support vision, hearing, smell, taste, or touch. That does not mean Huawei is about to ship a Neuralink rival next quarter. It does mean they are trying to own one of the low-level control layers that any serious neurostimulation stack may need.

The patent says the brain computer interface field is moving toward smaller, denser electrodes because they can target more precise regions of the brain. The problem is physics. A smaller electrode has less surface area in contact with tissue, which means the stimulator has to work harder to push the same signal through. Higher voltage, more electrical stress, less margin for error before something goes wrong.

People have been hurt in the wider neurostimulator world when electrical conditions got out of hand. In a 2005 case report, doctors described a patient with a permanent neurological injury caused by heating of a deep brain stimulation electrode during MRI. 

The FDA has also warned that implantable neurostimulators can run into trouble during CT imaging. The reported problems included pain, shocks, dizziness, shaking, overstimulation, burning sensation, and devices turning on or off. It is strong evidence that when electrical stimulation systems misbehave, the harm is very real.

Then there is the operational mess. In 2023, the FDA announced a Class I recall covering certain Abbott neurostimulation devices after problems with MRI mode. The agency said there had been 186 reported incidents and 73 reported injuries, and some patients could need surgery to replace the device. That kind of story is poison for a category trying to move from breakthrough demo to normal medical product.

Huawei may never need to build the surgery robot or run the clinic to win here. Its own IP page says the company wants to “proactively build high-value patent portfolios” and “provide safeguards for the company’s business operations worldwide.” 

Huawei says it ended 2024 with more than 150,000 active patents and more than 230 patent licensing and cross-license agreements, while WIPO says Huawei was again the top PCT filer in 2024 with 6,600 published applications. (huawei)

Reuters reported this month that Beijing elevated brain-computer interfaces into its latest five-year plan, wants major breakthroughs by 2027, and aims to cultivate two or three world-class brain-computer interface firms by 2030. The same report said China’s domestic brain-computer interface market is expected to reach about $809 million by 2027. Yao Dezhong, director of the Sichuan Institute of Brain Science, said that “after another three to five years” brain computer interface products could move toward “actual practical service for the public.” That is the window Huawei is patenting into. (Reuters)

And it is not just China. Apple said in 2025 that iOS, iPadOS, and visionOS would add a new protocol to support Switch Control for brain computer interfaces. That does not mean Apple is building an implant. It does mean the broader ecosystem is starting to assume brain-linked inputs may become real enough to support at the operating-system level. (Apple)

The headline company on the implant side is still Neuralink. Reuters reported in January that Neuralink had 21 trial participants enrolled worldwide, and earlier this year Musk said the company aimed for “high-volume” production in 2026. Reuters also reported, citing investor documents reviewed by Bloomberg, that Neuralink is targeting more than $1 billion in annual revenue by 2031 and 20,000 implants per year. (Reuters)

The FDA issued final guidance in 2021 for implanted brain computer interfaces for patients with paralysis or amputation, and at a 2025 FDA-NIH workshop officials said that guidance helps “de-risk” development. In the same workshop, FDA speakers said PMA review looks for “reasonable assurance of the safety and effectiveness.” 

In Europe, the MDR puts implantable and Class III devices under heavier scrutiny and requires a public summary of safety and clinical performance. If your device stimulates human tissue, safety is a route to market. (U.S. Food and Drug Administration)

When control logic fails in an implanted stimulation product, it can become injury reports, recall costs, surgery, and reputational damage very quickly. A separate 2024 systematic review found the total cost of a DBS surgery can exceed $40,000, which gives you a rough sense of how expensive even one extra corrective procedure can be. (U.S. Food and Drug Administration)

If you strip this down to companies whose pitch is really about not hurting the patient, the list gets short fast. Synchron, the New York company behind the Stentrode, is an endovascular brain-computer interface that is implanted through the jugular vein instead of through open-brain surgery. In its first-in-human safety paper in JAMA Neurology, researchers said the approach offered a “favorable safety profile,” and in Synchron’s later U.S. COMMAND study the company said all six patients met the primary endpoint of no device-related serious adverse events resulting in death or permanent increased disability over 12 months. Synchron then raised $200 million in a 2025 Series D to push commercialization. (Endovascular Today)

Just next door, you have companies proving that investors and customers will pay for safer, more controlled stimulation even when the product is not a pure brain-computer interface. Saluda Medical sells the Evoke System for chronic pain, a closed-loop spinal cord stimulator that “senses, measures, and adjusts on every pulse” instead of leaving therapy to guesswork. Saluda closed a $100 million financing in January 2025, then raised about A$230.8 million, roughly US$150 million, in its December 2025 IPO and later reaffirmed US$85 million in FY26 revenue guidance. (Saluda Medical US)

Then there is NeuroPace, which is even closer to the brain. Its Responsive NeuroStimulation (RNS) System is an FDA-approved implant for epilepsy that constantly monitors brainwaves, detects unusual activity that may lead to a seizure, and responds in real time with brief pulses to disrupt it. NeuroPace reported $100.0 million in 2025 revenue, including $81.7 million from the RNS System, and said its latest PMA supplement submission was backed by 18-month results showing a 77% median seizure reduction with a favorable safety profile. (NeuroPace, Inc)

The market is already rewarding companies that can say, with a straight face, that “our device monitors itself, adjusts in real time, and fits inside a safety story regulators can live with.” The FDA’s own brain-computer interface guidance is built around non-clinical testing and clinical design for implanted devices, which tells you exactly where the bar is. In that kind of market, Huawei’s patent is a claim on the safety layer that future brain computer interface sellers may need to license, build around, or compete against.

Brain-computer interfaces may look like a land grab for attention, but Huawei is betting the real leverage sits deeper in the stack. If this market takes off, the winners will need hardware that can keep patients safe when the signal gets messy. 

This filing is less about reading your mind, and more about making sure the machine does not hurt you. Think this safety layer becomes a licensing goldmine, or just another patent that never leaves the drawer?

You can read the full patent for yourself here: US 20260029849, Method for Controlling Stimulator, Stimulator, Brain-Computer Interface System, and Chip.